Cost-effectiveness of etranacogene dezaparvovec compared to eftrenonacog alfa for the treatment of adult patients with severe and moderately severe haemophilia B in Sweden
Open Access
- 4 October 2026
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2448-2463
Abstract
Haemophilia B is a rare X-chromosome linked bleeding disorder characterised by a deficiency of coagulation factor IX (FIX)1,2. In 2023, haemophilia B resulted in an estimated 38,000 cases worldwide...Keywords
Funding Information
- CSL Behring
This publication has 34 references indexed in Scilit:
- Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USAApplied Health Economics and Health Policy, 2024
- Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in GermanyPharmacoEconomics - Open, 2024
- Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trialThe Lancet Haematology, 2024
- High use of pain, depression, and anxiety drugs in hemophilia: more than 3000 people with hemophilia in an 11-year Nordic registry studyResearch and Practice in Thrombosis and Haemostasis, 2023
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic EvaluationsValue in Health, 2022
- Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferencesQuality of Life Research, 2019
- Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC StudyPharmacoEconomics, 2017
- The Impact of Haemophilia Complications on Health-Related Quality of Life for Adults with Severe HaemophiliaValue in Health, 2016
- Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in HemophiliaValue in Health, 2012
- Pettersson Score2008